This study aimed to characterise and compare the absorption pharmacokinetics of a single subcutaneous dose of @entity1288 in critically ill @entity1 and healthy subjects. Blood samples taken at intervals from two minutes to eight hours after a subcutaneous dose of @entity1288 in @entity1 (5 mg) and healthy volunteers (10 mg) were assayed using high performance liquid chromatography. Data were analysed using a non-compartmental approach and presented as mean (SD). Parameters were corrected for dose differences between the groups assuming linear kinetics. Ten @entity1 (eight male, two female) and seven healthy male subjects were included. Maximum venous concentration and area under the concentration curve were approximately two-fold lower in the @entity1 group for an equivalent dose, suggesting either reduced bioavailability or increased clearance: maximum venous concentration 0.14    0.06 vs 0.05    0.02   g/ml (P <0.0001); area under the concentration curve 19.50    9.15 vs 9.72    2.71   g/ml/minute (P <0.001) respectively. However, time to maximum venous concentration and mean residence time were not different, suggesting similar absorption rates: time to maximum venous concentration 22.10    18.0 vs 20.50    16.10 minutes (P=0.81); mean residence time 353    191 vs 291    80 minutes (P=0.26). Kinetic parameters were less variable in @entity1 than in volunteers. The @entity1 therefore had reduced exposure to subcutaneous @entity1288 . This warrants further model-based analysis and experimentation. Dose regimens for subcutaneous @entity1288 developed in healthy volunteers cannot be directly translated to critically ill @entity1 .

Pharmacokinetics of XXXX after subcutaneous administration in a critically ill population compared with a healthy cohort.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1288 :: ('MESH:D010098', 'Chemical') :: ['oxycodone']
@entity1288 :: (MESH:D010098,Chemical) :: ['oxycodone']
